Skip To Main Content
Er’jiang Tang on Muck Rack

Er’jiang Tang

As seen in: Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Er’jiang

Contact Er’jiang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer

|
By Dongdong Zhou, Wenjun Wang, Jianming Huang, Jie Liu, Chao Zheng, Kai Zhang, Peng Xiong, Xin Chu, Weisong Li, Dongqin Liu, Xiangfu Zeng, Yong Zheng, Shuyong Zhang, Er’jiang Tang, Youban Xiao, Ruxia Hu, Feiqi Wang, Dexian Zheng, Liefeng Wang
| Cell Reports Medicine Verified
Keywords advanced colorectal cancer DR5 CDK4 antibody-drug conjugate Oba01 abemaciclib synergetic effect Introduction Colorectal cancer (CRC) is the third most common causes of cancer-related death and the second in terms of mortality, accounting for 10% of all cancer cases and related death.1,2 Among 20% of newly diagnosed patients with metastatic CRC, less than 20% survive for more than 5 years,3,4 making it a major public health and socioeconomic concern.
Open in Who Shared Issue with article?
See all 1 articles